Abstract: Provided herein are compositions and methods related to extending viable preservation of organs and tissues. The compositions comprise superoxide dismutase, catalase, vitamin E, and glutathione, and optionally, a preservation solution (e.g., University of Wisconsin solution). Also provided are methods of preserving the contractile function of a contractile tissue, as well as kits comprising the compositions described herein.

Abstract: A manually-operated quantification soft tissue mobilization (QSTM) device includes a pressure applicator and a sensor member. The pressure applicator is configured to enable a user to dynamically apply a stroking mechanical force as the pressure applicator is moved over an area treatment areas of a patient's soft tissue. The sensor member including an accelerometer and a gyrometer is configured to determine various parameters of the dynamically applied stroking mechanical force in three dimensions as the pressure applicator is moved over the treatment areas of the patient's soft tissue. These parameters include a force magnitude in three dimensions, an angle in multiple axes, a stroke position, a stroke frequency, a sensed vibration magnitude at dominant spectral frequencies, and/or a rate of the stroking mechanical force dynamically applied to the soft tissue.

Abstract: The present disclosure provides methods and compositions for treating tissue to preserve and/or rescue tissue from ischemic and/or reperfusion injury and methods for assessing ischemic and/or injuries in cardiac tissue. The disclosed compositions comprise at least a portion of mesenchymal stem cell-conditioned medium.

Abstract: EMAPII is a monocyte- and endothelial cell-activating protein with prominent pro-apoptotic activity on endothelial and epithelial cells. Provided herein are compositions and methods for treating or preventing endothelial and epithelial apoptosis induced by EMAPII. More particularly, provided herein are compositions and methods for treating or preventing Influenza A virus (IAV)-induced weight loss, impairment of blood oxygenation, lung edema, and endothelial/epithelial apoptosis associated with IAV infections. In addition, anti-EMAPII therapy provides a novel complementary treatment strategy to existing anti-viral and anti-inflammatory approaches.

Abstract: EMAPII is a monocyte- and endothelial cell-activating protein with prominent pro-apoptotic activity on endothelial and epithelial cells. Provided herein are compositions and methods for treating or preventing endothelial and epithelial apoptosis induced by EMAPII. More particularly, provided herein are compositions and methods for treating or preventing Influenza A virus (IAV)-induced weight loss, impairment of blood oxygenation, lung edema, and endothelial/epithelial apoptosis associated with IAV infections.

Abstract: A manual soft tissue device including a pressure applicator and a sensor member configured to determine at least one of a magnitude, an angle, a stroke frequency, and a rate of force applied to soft tissue by the pressure applicator.

Abstract: The present disclosure provides methods and compositions for treating tissue to preserve and/or rescue tissue from ischemic and/or reperfusion injury and methods for assessing ischemic and/or injuries in cardiac tissue. The disclosed compositions comprise at least a portion of mesenchymal stem cell-conditioned medium.

Abstract: A combination of therapeutic factors derived from non-adherent or poorly adherent stromal vascular fraction (SVF) cells exposed to protein-free basal medium are disclosed.

Abstract: Implantable biomedical device leads comprising liquid conductors. In an exemplary embodiment of a lead for use in a biomedical application of the present disclosure, the lead comprises a lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough, and an electrically conductive composition positioned within the first interior lumen, the electrically conductive composition comprising a metal in a liquid state at or below about 98° F. In another embodiment, the electrically conductive composition is selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof. In various embodiments, the metallic electrically conductive composition is used along with a second non-metallic electrically conductive composition such as a conductive polymer, an electrically conductive liquid, an electrically conductive gel, or combinations thereof.

Abstract: Methods are provided for promoting angiogenesis in a mammal, such methods including the administration of therapeutic quantity of adipose-derived stromal cells to a mammal such that therapeutic angiogenesis occurs.

Abstract: Adipose tissue-derived stromal cells and methods of isolating and using the same. In at least one embodiment of isolated adipose tissue-derived stromal cells of the present disclosure, the cells are isolated by performing adipose tissue resection or suction on a mammalian patient, dissecting tissue obtained from said tissue resection or suction and dissociating said tissue into a cell suspension, removing adipocytes from the cell suspension, culturing the adipocyte-depleted cell suspension in EGM-2-MV media, and isolating adipose tissue-derived stromal cells secreting vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and granulocyte-colony stimulating factor (G-CSF).

Abstract: Methods are provided for isolating adipose derived stromal cells from an animal by extracting adipose tissue from the patient, dissecting the tissue, dissociating the tissue into a cell suspension, removing the adipocytes, exposing the cell suspension to red cell lysis buffer, and isolating adipose derived stromal cells.

Abstract: The present invention relates to a methods, compositions, and admixtures which prevent the aggregation of a population of adipose stromal cells (ASCs), such as an isolated population of adipose stromal cells. In some embodiments, the present invention relates to admixtures and methods of use thereof comprising a population of ASC and a modulator of ASC aggregation. In some embodiments, a modulator of ASC aggregation includes, for example, ionic agents (e.g., heparin), chelating agents (e.g., EDTA), proteolytic agents.(e.g., trypsin or dispase), and agents which inhibit the expression of cell surface receptors and molecules on the surface of ASCs (e.g., inhibitors of integrins expression). In some embodiments, the methods to block ASC aggregation and the admixtures are useful in use of the ASCs to treat various diseases and/or conditions, and increases the safety and/or efficiency of ASCs.

Abstract: Cell based compositions and methods are provided for inducing the formation of vascular structures in a warm blooded vertebrate. In one embodiment the composition comprises purified endothelial progenitor cells and adipose stromal cells and the method of stimulating the formation of vascular structures comprises the steps of implanting the composition in a host organism.

Abstract: Methods are provided for isolating adipose derived stromal cells from an animal by extracting adipose tissue from the patient, dissecting the tissue, dissociating the tissue into a cell suspension, removing the adipocytes, exposing the cell suspension to red cell lysis buffer, and isolating adipose derived stromal cells.

Abstract: A system for treating a patient's heart which comprises a means to form channels in the heart wall and a means to deliver a therapeutic or diagnostic agent into the channels. Additionally, the system may comprise a means to retain the agent within the channels for a useful period of time. The system may be configured to be introduced percutaneously or intraoperatively. The system generally comprises an elongated, flexible lasing transmission means having a laser radiation emitting means and an delivery lumen opening at the distal end. Practice of the invention comprises forming channels in the heart wall and delivering a therapeutic or diagnostic agent into the channel. Gene therapy agents of this invention comprise vectors for transferring genetic information to the heart tissue in vivo or harvested cells which have been genetically engineered in vitro. Additionally, the invention may comprise retaining the agent within the channels, for example, by incorporating the agent in a viscous carrier.

Abstract: A system and method for increasing the efficacy of stimulation signal therapy applied to selected tissue at a treatment site is disclosed. The method includes determining a stimulation signal capable of effecting desired results on the selected tissue and selectively modulating the stimulation signal such that the desired effect is achieved at the treatment site. The system includes a signal generator capable of generating a stimulation signal configured to produce a desired biologic effect on selected tissue at the treatment site, a modulator configured to selectively modulate the stimulation signal such that the stimulation signal correlates with at least one characteristic of the selected tissue and an emitter configured to apply the stimulation signal to the selected tissue.

Abstract: A system and method for treating cardiovascular disease utilizes electromagnetic fields (EMF) applied by non-invasive or minimally invasive procedures. The EMF is applied to existing vascular structure to modulate blood flow and blood vessel growth in the patient. In one embodiment, a structure of electromagnetic coils is placed about a desired treatment zone to apply an EMF to the zone on the order of 104-10 T. For cardiac angiogenesis, coils can be positioned on the anterior chest wall and on the back at the level of the heart. Various coil configurations are contemplated to yield appropriate field intensities at the treatment zone. In another embodiment, coils can be implanted within the patient and placed within or overlying the treatment zone incorporating several aspects, such as frequency components, the use of ca carrier frequency, pulse shape, duty cycle, and total time exposure to the EMF.

Abstract: Methods and compositions are provided for intra-pericardial administration of anti-microtubule agents, suitable for use in treating or preventing a variety of diseases of the pericardium, heart, or, coronary vasculature.

Abstract: An apparatus for treating a body structure with radiation and a method for using the same. The apparatus comprising a concentrator for receiving a solution comprising a radioactive material and for increasing the concentration of the radioactive material in solution; a calibrator operatively associated with the concentrator for measuring a level of radiation associated with the radioactive material; and a delivery unit for transferring the solution directly from the apparatus to a balloon catheter.